Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:38 pm Purchase | 2023-12-31 | 13G | enVVeno Medical Corporation NVNO | PERCEPTIVE ADVISORS LLC | 1,394,716 9.900% | 457,201 (+48.77%) | Filing History |
| 2024-02-14 4:38 pm Purchase | 2023-12-31 | 13G | Amicus Therapeutics, Inc. FOLD | PERCEPTIVE ADVISORS LLC | 28,057,456 9.600% | 414,539 (+1.50%) | Filing History |
| 2024-02-14 4:36 pm Unchanged | 2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | PERCEPTIVE ADVISORS LLC | 3,007,858 13.600% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:36 pm Sale | 2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | PERCEPTIVE ADVISORS LLC | 1,869,125 2.800% | -4,219,208 (-69.30%) | Filing History |
| 2024-02-14 4:34 pm Purchase | 2023-12-31 | 13G | Celcuity Inc. CELC | PERCEPTIVE ADVISORS LLC | 1,481,300 6.100% | 40,000 (+2.78%) | Filing History |
| 2024-02-14 4:32 pm Sale | 2023-12-31 | 13G | Veru Inc. VERU | PERCEPTIVE ADVISORS LLC | 5,584,699 3.800% | -2,273,312 (-28.93%) | Filing History |
| 2024-02-14 4:31 pm Purchase | 2023-12-31 | 13G | Evolus, Inc. EOLS | PERCEPTIVE ADVISORS LLC | 3,963,424 6.900% | 876,820 (+28.41%) | Filing History |
| 2024-02-14 4:29 pm Unchanged | 2024-02-14 | 13D | Lyra Therapeutics, Inc. LYRA | PERCEPTIVE ADVISORS LLC | 12,757,563 24.300% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:29 pm Purchase | 2023-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | PERCEPTIVE ADVISORS LLC | 11,979,415 4.700% | 2,007,635 (+20.13%) | Filing History |
| 2024-02-14 4:27 pm Sale | 2023-12-31 | 13G | Verona Pharma plc VRNA | PERCEPTIVE ADVISORS LLC | 3,866,214 4.800% | -596,452 (-13.37%) | Filing History |
| 2024-02-14 4:27 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,606,679 7.200% | 0 (Unchanged) | Filing History |
| 2024-02-12 4:16 pm Purchase | 2024-02-01 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | PERCEPTIVE ADVISORS LLC | 3,260,013 5.500% | 3,260,013 (New Position) | Filing History |
| 2024-02-09 7:51 pm Purchase | 2024-01-30 | 13D | Trinity Biotech plc TRIB | PERCEPTIVE ADVISORS LLC | 11,200,000 26.800% | 11,200,000 (New Position) | Filing History |
| 2024-02-05 4:14 pm Purchase | 2024-02-01 | 13D | Astria Therapeutics, Inc. ATXS | PERCEPTIVE ADVISORS LLC | 6,485,420 11.900% | 2,857,727 (+78.78%) | Filing History |
| 2024-01-29 4:53 pm Purchase | 2024-01-18 | 13G | Viridian Therapeutics, Inc. VRDN | PERCEPTIVE ADVISORS LLC | 4,022,066 6.700% | 4,022,066 (New Position) | Filing History |
| 2024-01-19 4:37 pm Purchase | 2024-01-09 | 13G | Fusion Pharmaceuticals Inc. FUSN | PERCEPTIVE ADVISORS LLC | 4,737,194 6.500% | 4,737,194 (New Position) | Filing History |
| 2024-01-12 5:11 pm Purchase | 2024-01-11 | 13D | Solid Biosciences Inc. SLDB | PERCEPTIVE ADVISORS LLC | 6,925,028 18.600% | 3,423,763 (+97.79%) | Filing History |
| 2024-01-02 4:11 pm Purchase | 2023-12-20 | 13G | Nuvalent, Inc. NUVL | PERCEPTIVE ADVISORS LLC | 2,917,991 5.100% | 2,917,991 (New Position) | Filing History |
| 2023-12-29 5:15 pm Purchase | 2023-12-27 | 13D | Athira Pharma, Inc. ATHA | PERCEPTIVE ADVISORS LLC | 5,458,448 14.300% | 647,299 (+13.45%) | Filing History |
| 2023-12-26 4:15 pm Purchase | 2023-12-14 | 13G | Celcuity Inc. CELC | PERCEPTIVE ADVISORS LLC | 1,441,300 5.700% | 1,441,300 (New Position) | Filing History |